Erin Walczykowski
Psychiatric/Mental Health · Washington, DCNPI 1316499825
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,660 of the $349,232 with a category attached, or 76.9%. Neurocrine Biosciences, Inc. accounts for 72.9% of it on its own, with 11 other manufacturers making up the rest. Among psychiatric/mental health clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 565 payments — averaging $618.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$255K
- Alkermes, Inc.$41K
- Otsuka America Pharmaceutical, Inc.$32K
- AbbVie$19K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$638
- Lundbeck LLC$624
- plus $1K from 6 others
What the payments were for
- Consulting fees$30,8569%
- Speaking & faculty fees$268,66077%
- Travel & lodging$36,40110%
- Food & beverage$13,2074%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 244 | $254,576 |
| Alkermes, Inc. | 89 | $41,093 |
| Otsuka America Pharmaceutical, Inc. | 76 | $32,038 |
| AbbVie | 70 | $19,175 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $638 |
| Lundbeck LLC | 32 | $624 |
| Johnson & Johnson | 16 | $452 |
| Teva Pharmaceuticals USA, Inc. | 13 | $276 |
| Sunovion Pharmaceuticals Inc. | 8 | $174 |
| Corium, LLC | 2 | $116 |
| Indivior Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$251,562
- LYBALVI$117,825
- ARISTADA$46,203
- ABILIFY MAINTENA$31,143
- ABILIFY ASIMTUFII$27,661
- VRAYLAR$18,037
- ARISTADA INITIO$4,615
- CAPLYTA$257
- Austedo XR$125
How this compares
$349,232 in reported general payments places this provider in the 95th percentile of 137 psychiatric/mental health providers in District of Columbia.
See all psychiatric/mental health providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 35 | $284,174 |
| Invega TrinzaPaliperidone Palmitate | 12 | $131,729 |
| Invega SustennaPaliperidone Palmitate | 32 | $90,375 |
| Abilify AsimtufiiAripiprazole | 12 | $72,223 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $34,424 |
| Risperdal ConstaRisperidone Microspheres | 13 | $33,794 |
| VraylarCariprazine Hcl | 12 | $18,011 |
| Haloperidol Decanoate | 125 | $4,946 |
| Haloperidol | 78 | $2,913 |
| Oxcarbazepine | 59 | $2,229 |
| Ramelteon | 23 | $2,222 |
| Benztropine Mesylate | 171 | $2,137 |
| Lurasidone Hcl | 60 | $2,027 |
| Fluphenazine Decanoate | 11 | $1,592 |
| Olanzapine | 33 | $1,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $254,576 | $284,17435 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $452 | $255,89857 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $32,038 | $72,22312 claims |
| Alkermes, Inc.Lybalvi | $41,093 | $34,42421 claims |
| AbbVieVraylar | $19,175 | $18,01112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 psychiatric/mental health providers in District of Columbia.
Other psychiatric/mental health in Washington
- Caroline BonuWashington$16K
- Miriam EzenwakaWashington$6K
- Orin GreeneWashington$4K
- Hope AchoronyeWashington$4K
- Samantha HyltonWashington$4K
- Nkechi OnwucheWashington$4K
- Emmanuel Kamdem SangoWashington$4K
- Arithia HardenWashington$4K
- Zion DestaWashington$4K
- Collette OdiboWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.